A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

Abstract Background Inhibition of interleukin (IL)-13, a Type 2 inflammatory mediator in asthma, improves lung function and reduces exacerbations; however, more effective therapies are needed. A subset of asthma patients also exhibits elevated IL-17, which is associated with greater disease severity...

Full description

Bibliographic Details
Main Authors: Tracy L. Staton, Kun Peng, Ryan Owen, David F. Choy, Christopher R. Cabanski, Alice Fong, Flavia Brunstein, Kathila R. Alatsis, Hubert Chen
Format: Article
Language:English
Published: BMC 2019-01-01
Series:BMC Pulmonary Medicine
Subjects:
IL-13
IL-17
Asthma
Anti-drug antibodies
Immunogenicity
Phase 1
Online Access:http://link.springer.com/article/10.1186/s12890-018-0763-9

Internet

http://link.springer.com/article/10.1186/s12890-018-0763-9

Similar Items